BDBM50311017 CHEMBL1078178::Momelotinib::N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide::US10112907, Example 00019::US10766894, Compound TABLE 1.4::US11203595, TABLE 1.4::US9469613, CYT-0387

SMILES O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1

InChI Key InChIKey=ZVHNDZWQTBEVRY-UHFFFAOYSA-N

Data  29 IC50  8 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 33 hits for monomerid = 50311017   

TargetTyrosine-protein kinase JAK3(Human)
Cadila Healthcare

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 134nMAssay Description:Inhibition of human JAK3 kinase domainMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK1 [866-1154](Human)
Novartis

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 20nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Novartis

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 20nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Novartis

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 210nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 30nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 18nMAssay Description:Inhibition of JAK 2 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 11nMAssay Description:Inhibition of JAK 1 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 18nMAssay Description:Inhibition of human JAK1 kinase domainMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 15nMAssay Description:Inhibition of human JAK2 kinase domainMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Novartis

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 30nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSerine/threonine-protein kinase Nek1(Human)
University of North Carolina At Chapel Hill

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataKd: <100nMAssay Description:Inhibition of NEK1 (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetSerine/threonine-protein kinase Nek3(Human)
University of North Carolina At Chapel Hill

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataKd: <100nMAssay Description:Inhibition of NEK3 (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetSerine/threonine-protein kinase Nek9(Human)
University of North Carolina At Chapel Hill

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataKd: <100nMAssay Description:Inhibition of NEK9 (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetSerine/threonine-protein kinase Nek9(Human)
University of North Carolina At Chapel Hill

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 100nMAssay Description:Inhibition of NEK9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 11nMAssay Description:Inhibition of recombinant GST-tagged JAK1 (unknown origin) expressed in baculovirus infected Sf9 cells in the presence of ATP by Alphascreen assayMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 18nMAssay Description:Inhibition of recombinant GST-tagged JAK2 (unknown origin) expressed in baculovirus infected Sf9 cells in the presence of ATP by Alphascreen assayMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Cadila Healthcare

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 155nMAssay Description:Inhibition of recombinant GST-tagged JAK3 (unknown origin) expressed in baculovirus infected Sf9 cells in the presence of ATP by Alphascreen assayMore data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetFerrochelatase, mitochondrial [R115L](Human)
Technical University of Munich

LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataKd:  3.40E+3nMAssay Description:Briefly, 5 mg of a protein mixture of the four cell lines or a single cell line were incubated with compound dilution series in DMSO (3 nM, 10 nM, 30...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Cadila Healthcare

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 210nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 20nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 20nMAssay Description:The assays were performed in 384-well, low volume microtiter assay plates in a final reaction volume of 9 ul. Dose-response curves were generated by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 41nMAssay Description:Inhibition of JAK2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition and measured after...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 30nMpH: 7.5Assay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for recombinant human Jak1 (aa 866-1154), Jak2 (aa808-1132), J...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK3 [811-1124](Human)
Novartis

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 210nMpH: 7.5Assay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for recombinant human Jak1 (aa 866-1154), Jak2 (aa808-1132), J...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Novartis

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 20nMpH: 7.5Assay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for recombinant human Jak1 (aa 866-1154), Jak2 (aa808-1132), J...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK1 [866-1154](Human)
Novartis

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 20nMpH: 7.5Assay Description:A kinase selectivity panel which measures substrate peptide phosphorylation was set-up for recombinant human Jak1 (aa 866-1154), Jak2 (aa808-1132), J...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 11nMAssay Description:Inhibition of GST-tagged JAK1More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Cadila Healthcare

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 155nMAssay Description:Inhibition of GST-tagged JAK3 kinaseMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Csir-Indian Institute of Integrative Medicine

Curated by ChEMBL
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 18nMAssay Description:Inhibition of GST-tagged JAK2 kinaseMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetTGF-beta receptor type-1(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 205nM Kd:  670nMAssay Description:Biochemical binding assays (DiscoveRx) and in vitro enzyme inhibition assays (LanthaScreen, Life Technologies) were conducted to determine the bindin...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 107nM Kd:  19nMAssay Description:Biochemical binding assays (DiscoveRx) and in vitro enzyme inhibition assays (LanthaScreen, Life Technologies) were conducted to determine the bindin...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 405nM Kd:  1.00E+3nMAssay Description:Biochemical binding assays (DiscoveRx) and in vitro enzyme inhibition assays (LanthaScreen, Life Technologies) were conducted to determine the bindin...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetActivin receptor type-1(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50311017(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyri...)
Affinity DataIC50: 8nM Kd:  25nMAssay Description:Biochemical binding assays (DiscoveRx) and in vitro enzyme inhibition assays (LanthaScreen, Life Technologies) were conducted to determine the bindin...More data for this Ligand-Target Pair
In DepthDetails
US Patent